{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:19:09Z","timestamp":1793042349741,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-024-00582-z","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T04:03:11Z","timestamp":1723003391000},"page":"818-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals"],"prefix":"10.1007","volume":"13","author":[{"given":"Kahei","family":"Au","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar M.","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Mahawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Shabbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel W.","family":"le Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sombat","family":"Treeprasertsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Xiaoyan","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Sakran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoel Galvao","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kermansaravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Kow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Wei","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo V.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Stier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"AlSabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo J.","family":"Oviedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Chiappetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2341-3310","authenticated-orcid":false,"given":"Wah","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Global Obesity Collaborative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahei","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar M","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Mahawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Shabbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel W","family":"le Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sombat","family":"Treeprasertsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Xiaoyan","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Sakran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoel Galvao","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kermansaravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Kow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Wei","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo V","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Stier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"AlSabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo J","family":"Oviedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Chiappetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wah","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer Nabil","family":"Abdelbaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abouelazayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel Karim","family":"Abou-Mrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Abu-Abeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhaib","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Al-Momani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Amr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmatullah","family":"athar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selmy S","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Rasid","family":"Aykota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Haider","family":"Bangash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Blackham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Calikoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Yoshimia","family":"Castillo Vacaflor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleyman","family":"Cetinkunar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Tian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Costa-Pinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Carolina","family":"Batista Dantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"De Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viorel","family":"Dejeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugrul","family":"Demirel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Hayssam","family":"Elfawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosam M","family":"Elghadban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa Refaie","family":"Elkeleny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Moritz","family":"Felsenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Eduardo Garcia","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled Aly","family":"Gawdat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Ghazouani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juqiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Hee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Carolina","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ingallinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanpu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abd-Elfattah Morsi","family":"Kalmoush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik Ritza","family":"Kosai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Lainas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muffazal","family":"Lakdawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skye","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro R","family":"Martinez-Duartez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Materazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Anton","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Neimark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Ka-kei","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulellah Mohamedamin","family":"Niyaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryel Isgender","family":"Omarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo Ponce","family":"de Leon-Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri J","family":"Pournaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjaak","family":"Pouwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingshun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynaldo Martins","family":"e Quinino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittal Sree","family":"Rama Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Peter","family":"Rheinwalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Martin Bianco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Ruiz-Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ruiz-Ucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhvinder Singh","family":"Saggu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elgun","family":"Samadov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Saviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Seyedyousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab Shahabi","family":"Shahmiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongpeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Snoekx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Qin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kon Voi","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Tolone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaher","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthep","family":"Udomsawaengsup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Wafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoqi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thejana Kamil","family":"Wijeratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baowen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanna","family":"Zakeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Zerrweck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio Zuluaga","family":"Zuluaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"issue":"4","key":"582_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595.","journal-title":"Gut"},{"key":"582_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.02.007","author":"L Miao","year":"2024","unstructured":"Miao L, Targher G, Byrne CD, et al. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024. https:\/\/doi.org\/10.1016\/j.tem.2024.02.007.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"582_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","volume":"21","author":"G Feng","year":"2024","unstructured":"Feng G, Valenti L, Wong VW, et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2024;21(1):46\u201356. https:\/\/doi.org\/10.1038\/s41575-023-00846-4.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"582_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3350\/cmh.2022.0239","volume":"28","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Zou B, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022;28(4):841\u201350. https:\/\/doi.org\/10.3350\/cmh.2022.0239.","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"582_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.21037\/hbsn-23-539","volume":"12","author":"F Gao","year":"2023","unstructured":"Gao F, Chen G, Byrne CD, et al. Metabolic dysfunction-associated fatty liver disease and hepatocellular carcinoma: present and future. Hepatobiliary Surg Nutr. 2023;12(6):945\u20139485. https:\/\/doi.org\/10.21037\/hbsn-23-539.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"582_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11102761","author":"Y Takahashi","year":"2023","unstructured":"Takahashi Y, Dungubat E, Kusano H, Fukusato T. Pathology and pathogenesis of metabolic dysfunction-associated steatotic liver disease-associated hepatic tumors. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11102761.","journal-title":"Biomedicines"},{"issue":"9","key":"582_CR7","doi-asserted-by":"publisher","first-page":"100810","DOI":"10.1016\/j.jhepr.2023.100810","volume":"5","author":"BG Song","year":"2023","unstructured":"Song BG, Choi SC, Goh MJ, et al. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma. JHEP Rep. 2023;5(9):100810. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100810.","journal-title":"JHEP Rep"},{"issue":"6","key":"582_CR8","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.jhep.2023.08.018","volume":"79","author":"F Ebrahimi","year":"2023","unstructured":"Ebrahimi F, Hagstr\u00f6m H, Sun J, et al. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study. J Hepatol. 2023;79(6):1374\u201384. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.018.","journal-title":"J Hepatol"},{"issue":"716","key":"582_CR9","doi-asserted-by":"publisher","first-page":"eadi0759","DOI":"10.1126\/scitranslmed.adi0759","volume":"15","author":"S Wang","year":"2023","unstructured":"Wang S, Friedman SL. Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). Sci Transl Med. 2023;15(716):eadi0759. https:\/\/doi.org\/10.1126\/scitranslmed.adi0759.","journal-title":"Sci Transl Med"},{"issue":"6","key":"582_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","volume":"79","author":"PN Newsome","year":"2023","unstructured":"Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver. J Hepatol. 2023;79(6):1557\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.033.","journal-title":"J Hepatol"},{"issue":"4","key":"582_CR11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"XD Zhou","year":"2023","unstructured":"Zhou XD, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773\u201391. https:\/\/doi.org\/10.1007\/s12072-023-10543-8.","journal-title":"Hepatol Int"},{"key":"582_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.01.032","author":"LA Abushamat","year":"2024","unstructured":"Abushamat LA, Shah PA, Eckel RH, et al. The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis. Clin Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.cgh.2024.01.032.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10213","key":"582_CR13","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/s0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(19)32517-6.","journal-title":"Lancet"},{"issue":"11","key":"582_CR14","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919\u201328. https:\/\/doi.org\/10.1038\/s41591-023-02603-1.","journal-title":"Nat Med"},{"issue":"6","key":"582_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"issue":"4","key":"582_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/hep4.1657","volume":"5","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Bashir M, Moussa SE, et al. Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Hepatol Commun. 2021;5(4):573\u201388. https:\/\/doi.org\/10.1002\/hep4.1657.","journal-title":"Hepatol Commun"},{"issue":"12","key":"582_CR17","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1111\/bph.15427","volume":"178","author":"A Kannt","year":"2021","unstructured":"Kannt A, Wohlfart P, Madsen AN, et al. Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. Br J Pharmacol. 2021;178(12):2412\u201323. https:\/\/doi.org\/10.1111\/bph.15427.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"582_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/s2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362\u201373. https:\/\/doi.org\/10.1016\/s2468-1253(19)30383-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"582_CR19","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717\u201330. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.042.","journal-title":"Gastroenterology"},{"issue":"1","key":"582_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.soard.2017.09.005","volume":"14","author":"H Garg","year":"2018","unstructured":"Garg H, Aggarwal S, Shalimar, et al. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients. Surg Obes Relat Dis. 2018;14(1):81\u201391. https:\/\/doi.org\/10.1016\/j.soard.2017.09.005.","journal-title":"Surg Obes Relat Dis"},{"issue":"4","key":"582_CR21","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1097\/js9.0000000000001078","volume":"110","author":"R Hu","year":"2024","unstructured":"Hu R, Wu B, Wang C, et al. Assessment of transient elastography in diagnosing MAFLD and the early effects of sleeve gastrectomy on MAFLD among the Chinese population. Int J Surg. 2024;110(4):2044\u201354. https:\/\/doi.org\/10.1097\/js9.0000000000001078.","journal-title":"Int J Surg"},{"issue":"1","key":"582_CR22","doi-asserted-by":"publisher","first-page":"Cd010542","DOI":"10.1002\/14651858.CD010542.pub2","volume":"1","author":"CS Pavlov","year":"2015","unstructured":"Pavlov CS, Casazza G, Nikolova D, et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev. 2015;1(1):Cd010542. https:\/\/doi.org\/10.1002\/14651858.CD010542.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"582_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/apt.13524","volume":"43","author":"CS Pavlov","year":"2016","unstructured":"Pavlov CS, Casazza G, Nikolova D, et al. Systematic review with meta-analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease. Aliment Pharmacol Ther. 2016;43(5):575\u201385. https:\/\/doi.org\/10.1111\/apt.13524.","journal-title":"Aliment Pharmacol Ther"},{"key":"582_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/v15081730","author":"L Rinaldi","year":"2023","unstructured":"Rinaldi L, Giorgione C, Mormone A, et al. Non-invasive measurement of hepatic fibrosis by transient elastography: a narrative review. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15081730.","journal-title":"Viruses"},{"issue":"4","key":"582_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00535-019-01635-0","volume":"55","author":"S Oeda","year":"2020","unstructured":"Oeda S, Takahashi H, Imajo K, et al. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan(\u00ae) M\/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol. 2020;55(4):428\u201340. https:\/\/doi.org\/10.1007\/s00535-019-01635-0.","journal-title":"J Gastroenterol"},{"issue":"3","key":"582_CR26","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","volume":"79","author":"JX Liang","year":"2023","unstructured":"Liang JX, Ampuero J, Niu H, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol. 2023;79(3):592\u2013604. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.025.","journal-title":"J Hepatol"},{"issue":"7","key":"582_CR27","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/s2468-1253(23)00066-3","volume":"8","author":"MA Tincopa","year":"2023","unstructured":"Tincopa MA, Loomba R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol. 2023;8(7):660\u201370. https:\/\/doi.org\/10.1016\/s2468-1253(23)00066-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"582_CR28","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264-1281.e1264. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036.","journal-title":"Gastroenterology"},{"issue":"10","key":"582_CR29","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Shankar SS, Yates KP, et al. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nat Med. 2023;29(10):2656\u201364. https:\/\/doi.org\/10.1038\/s41591-023-02539-6.","journal-title":"Nat Med"},{"issue":"4","key":"582_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jhep.2022.11.029","volume":"78","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Williams SA, Lavine JE, et al. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2023;78(4):693\u2013703. https:\/\/doi.org\/10.1016\/j.jhep.2022.11.029.","journal-title":"J Hepatol"},{"issue":"11","key":"582_CR31","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/s2468-1253(20)30252-1","volume":"5","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Ratziu V, Boursier J, et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(11):970\u201385. https:\/\/doi.org\/10.1016\/s2468-1253(20)30252-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"14","key":"582_CR32","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.3748\/wjg.v30.i14.1982","volume":"30","author":"J Trinks","year":"2024","unstructured":"Trinks J, Mascardi MF, Gadano A, Marciano S. Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we? World J Gastroenterol. 2024;30(14):1982\u20139. https:\/\/doi.org\/10.3748\/wjg.v30.i14.1982.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"582_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jhep.2011.06.010","volume":"56","author":"C Thoma","year":"2012","unstructured":"Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56(1):255\u201366. https:\/\/doi.org\/10.1016\/j.jhep.2011.06.010.","journal-title":"J Hepatol"},{"issue":"27","key":"582_CR34","doi-asserted-by":"publisher","first-page":"6318","DOI":"10.3748\/wjg.v22.i27.6318","volume":"22","author":"P Golabi","year":"2016","unstructured":"Golabi P, Locklear CT, Austin P, et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. World J Gastroenterol. 2016;22(27):6318\u201327. https:\/\/doi.org\/10.3748\/wjg.v22.i27.6318.","journal-title":"World J Gastroenterol"},{"key":"582_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.metabol.2016.12.006","volume":"68","author":"CN Katsagoni","year":"2017","unstructured":"Katsagoni CN, Georgoulis M, Papatheodoridis GV, et al. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017;68:119\u201332. https:\/\/doi.org\/10.1016\/j.metabol.2016.12.006.","journal-title":"Metabolism"},{"issue":"1","key":"582_CR36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","volume":"59","author":"MC Ryan","year":"2013","unstructured":"Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59(1):138\u201343. https:\/\/doi.org\/10.1016\/j.jhep.2013.02.012.","journal-title":"J Hepatol"},{"issue":"6","key":"582_CR37","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/liv.15264","volume":"42","author":"ES George","year":"2022","unstructured":"George ES, Reddy A, Nicoll AJ, et al. Impact of a Mediterranean diet on hepatic and metabolic outcomes in non-alcoholic fatty liver disease: The MEDINA randomised controlled trial. Liver Int. 2022;42(6):1308\u201322. https:\/\/doi.org\/10.1111\/liv.15264.","journal-title":"Liver Int"},{"issue":"7","key":"582_CR38","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/liv.13435","volume":"37","author":"S Zelber-Sagi","year":"2017","unstructured":"Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int. 2017;37(7):936\u201349. https:\/\/doi.org\/10.1111\/liv.13435.","journal-title":"Liver Int"},{"key":"582_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/nu16071030","author":"LJ Dobbie","year":"2024","unstructured":"Dobbie LJ, Burgess J, Hamid A, et al. Effect of a Low-Calorie Dietary Intervention on Liver Health and Body Weight in Adults with Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Overweight\/Obesity: A Systematic Review and Meta-Analysis. Nutrients. 2024. https:\/\/doi.org\/10.3390\/nu16071030.","journal-title":"Nutrients"},{"issue":"5","key":"582_CR40","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/s2213-8587(18)30037-8","volume":"6","author":"DD Wang","year":"2018","unstructured":"Wang DD, Hu FB. Precision nutrition for prevention and management of type 2 diabetes. Lancet Diabetes Endocrinol. 2018;6(5):416\u201326. https:\/\/doi.org\/10.1016\/s2213-8587(18)30037-8.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"582_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/nu9080913","author":"J de Toro-Mart\u00edn","year":"2017","unstructured":"de Toro-Mart\u00edn J, Arsenault BJ, Despr\u00e9s JP, Vohl MC. Precision nutrition: a review of personalized nutritional approaches for the prevention and management of metabolic syndrome. Nutrients. 2017. https:\/\/doi.org\/10.3390\/nu9080913.","journal-title":"Nutrients"},{"issue":"3","key":"582_CR42","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1017\/s0029665123003038","volume":"82","author":"C Sawicki","year":"2023","unstructured":"Sawicki C, Haslam D, Bhupathiraju S. Utilising the precision nutrition toolkit in the path towards precision medicine. Proc Nutr Soc. 2023;82(3):359\u201369. https:\/\/doi.org\/10.1017\/s0029665123003038.","journal-title":"Proc Nutr Soc"},{"issue":"18","key":"582_CR43","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675\u201385. https:\/\/doi.org\/10.1056\/NEJMoa0907929.","journal-title":"N Engl J Med"},{"issue":"3","key":"582_CR44","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jhep.2022.03.010","volume":"77","author":"S Wabitsch","year":"2022","unstructured":"Wabitsch S, McCallen JD, Kamenyeva O, et al. Metformin treatment rescues CD8(+) T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol. 2022;77(3):748\u201360. https:\/\/doi.org\/10.1016\/j.jhep.2022.03.010.","journal-title":"J Hepatol"},{"issue":"3","key":"582_CR45","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri N, Herring R, Kabler H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. J Hepatol. 2022;77(3):607\u201318. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.003.","journal-title":"J Hepatol"},{"issue":"10290","key":"582_CR46","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/s0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(20)32511-3.","journal-title":"Lancet"},{"issue":"7","key":"582_CR47","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322. https:\/\/doi.org\/10.1038\/s41591-018-0104-9.","journal-title":"Nat Med"},{"issue":"8","key":"582_CR48","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","volume":"20","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Willoughby CE, Singal AG, et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol. 2023;20(8):487\u2013503. https:\/\/doi.org\/10.1038\/s41575-023-00754-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"582_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103910","volume":"29","author":"S Wei","year":"2024","unstructured":"Wei S, Wang L, Evans PC, Xu S. NAFLD and NASH: etiology, targets and emerging therapies. Drug Discov Today. 2024;29(3): 103910. https:\/\/doi.org\/10.1016\/j.drudis.2024.103910.","journal-title":"Drug Discov Today"},{"issue":"2","key":"582_CR50","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hep.32358","volume":"76","author":"R Pais","year":"2022","unstructured":"Pais R, Aron-Wisnewsky J, Bedossa P, et al. Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology. 2022;76(2):456\u201368. https:\/\/doi.org\/10.1002\/hep.32358.","journal-title":"Hepatology"},{"issue":"10390","key":"582_CR51","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/s0140-6736(23)00634-7","volume":"401","author":"O Verrastro","year":"2023","unstructured":"Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet. 2023;401(10390):1786\u201397. https:\/\/doi.org\/10.1016\/s0140-6736(23)00634-7.","journal-title":"Lancet"},{"issue":"4","key":"582_CR52","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","volume":"159","author":"G Lassailly","year":"2020","unstructured":"Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159(4):1290-1301.e1295. https:\/\/doi.org\/10.1053\/j.gastro.2020.06.006.","journal-title":"Gastroenterology"},{"issue":"2","key":"582_CR53","doi-asserted-by":"publisher","first-page":"e190047","DOI":"10.1001\/jamanetworkopen.2019.0047","volume":"2","author":"MJ Klebanoff","year":"2019","unstructured":"Klebanoff MJ, Corey KE, Samur S, et al. Cost-effectiveness analysis of bariatric surgery for patients with nonalcoholic steatohepatitis cirrhosis. JAMA Netw Open. 2019;2(2):e190047. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0047.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"582_CR54","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528\u201362. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010.","journal-title":"Endocr Pract"},{"key":"582_CR55","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000786","author":"X Wang","year":"2024","unstructured":"Wang X, Zhang L, Dong B. Molecular mechanisms in MASLD\/MASH-related HCC. Hepatology. 2024. https:\/\/doi.org\/10.1097\/hep.0000000000000786.","journal-title":"Hepatology"},{"issue":"6","key":"582_CR56","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","year":"2016","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u2013402. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004.","journal-title":"J Hepatol"},{"issue":"8","key":"582_CR57","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/s2468-1253(22)00061-9","volume":"7","author":"S McPherson","year":"2022","unstructured":"McPherson S, Armstrong MJ, Cobbold JF, et al. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. Lancet Gastroenterol Hepatol. 2022;7(8):755\u201369. https:\/\/doi.org\/10.1016\/s2468-1253(22)00061-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"582_CR58","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/1744666x.2023.2294046","volume":"20","author":"J Schw\u00e4rzler","year":"2024","unstructured":"Schw\u00e4rzler J, Grabherr F, Grander C, et al. The pathophysiology of MASLD: an immunometabolic perspective. Expert Rev Clin Immunol. 2024;20(4):375\u201386. https:\/\/doi.org\/10.1080\/1744666x.2023.2294046.","journal-title":"Expert Rev Clin Immunol"},{"key":"582_CR59","doi-asserted-by":"publisher","DOI":"10.1097\/hc9.0000000000000298","author":"J Bai","year":"2023","unstructured":"Bai J, Zhu L, Mi W, et al. Multiscale integrative analyses unveil immune-related diagnostic signature for the progression of MASLD. Hepatol Commun. 2023. https:\/\/doi.org\/10.1097\/hc9.0000000000000298.","journal-title":"Hepatol Commun"},{"issue":"3","key":"582_CR60","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Allen AM, Dubourg J, et al. Challenges and opportunities in NASH drug development. Nat Med. 2023;29(3):562\u201373. https:\/\/doi.org\/10.1038\/s41591-023-02242-6.","journal-title":"Nat Med"},{"issue":"6","key":"582_CR61","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15(6):349\u201364. https:\/\/doi.org\/10.1038\/s41575-018-0009-6.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"582_CR62","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000860","author":"M Noureddin","year":"2024","unstructured":"Noureddin M. MASH clinical trials and drugs pipeline: An impending Tsunami. Hepatology. 2024. https:\/\/doi.org\/10.1097\/hep.0000000000000860.","journal-title":"Hepatology"},{"key":"582_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/biom13091369","author":"O Ugonabo","year":"2023","unstructured":"Ugonabo O, Udoh US, Rajan PK, et al. The current status of the liver liquid biopsy in MASH related HCC: overview and future directions. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13091369.","journal-title":"Biomolecules"},{"key":"582_CR64","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.2147\/dddt.S315724","volume":"15","author":"JM Fraile","year":"2021","unstructured":"Fraile JM, Palliyil S, Barelle C, et al. Non-Alcoholic Steatohepatitis (NASH) - a review of a crowded clinical landscape, driven by a complex disease. Drug Des Devel Ther. 2021;15:3997\u20134009. https:\/\/doi.org\/10.2147\/dddt.S315724.","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"582_CR65","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","volume":"43","author":"ML Hartman","year":"2020","unstructured":"Hartman ML, Sanyal AJ, Loomba R, et al. Effects of Novel Dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43(6):1352\u20135. https:\/\/doi.org\/10.2337\/dc19-1892.","journal-title":"Diabetes Care"},{"issue":"10019","key":"582_CR66","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/s0140-6736(15)00803-x","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679\u201390. https:\/\/doi.org\/10.1016\/s0140-6736(15)00803-x.","journal-title":"Lancet"},{"issue":"6","key":"582_CR67","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/s2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511\u201322. https:\/\/doi.org\/10.1016\/s2468-1253(23)00068-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"582_CR68","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","volume":"16","author":"R Shetty","year":"2022","unstructured":"Shetty R, Basheer FT, Poojari PG, et al. Adverse drug reactions of GLP-1 agonists: A systematic review of case reports. Diabetes Metab Syndr. 2022;16(3):102427. https:\/\/doi.org\/10.1016\/j.dsx.2022.102427.","journal-title":"Diabetes Metab Syndr"},{"issue":"4","key":"582_CR69","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/s2468-1253(21)00261-2","volume":"7","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol. 2022;7(4):367\u201378. https:\/\/doi.org\/10.1016\/s2468-1253(21)00261-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"582_CR70","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K, et al. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-Label. Active-Controlled Trial Diabetes Care. 2022;45(9):2064\u201375. https:\/\/doi.org\/10.2337\/dc21-2049.","journal-title":"Active-Controlled Trial Diabetes Care"},{"issue":"1","key":"582_CR71","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","volume":"14","author":"AMC Ong Lopez","year":"2024","unstructured":"Ong Lopez AMC, Pajimna JAT. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Sci Rep. 2024;14(1):2122. https:\/\/doi.org\/10.1038\/s41598-024-52603-5.","journal-title":"Sci Rep"},{"issue":"3","key":"582_CR72","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s13679-022-00474-0","volume":"11","author":"SA Polyzos","year":"2022","unstructured":"Polyzos SA, Goulis DG, Giouleme O, et al. Anti-obesity medications for the management of nonalcoholic fatty liver disease. Curr Obes Rep. 2022;11(3):166\u201379. https:\/\/doi.org\/10.1007\/s13679-022-00474-0.","journal-title":"Curr Obes Rep"},{"key":"582_CR73","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.014.","journal-title":"Metabolism"},{"key":"582_CR74","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fendo.2020.00070","volume":"11","author":"CS Pan","year":"2020","unstructured":"Pan CS, Stanley TL. Effect of weight loss medications on hepatic steatosis and steatohepatitis: a systematic review. Front Endocrinol (Lausanne). 2020;11:70. https:\/\/doi.org\/10.3389\/fendo.2020.00070.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"582_CR75","doi-asserted-by":"publisher","first-page":"155835","DOI":"10.1016\/j.metabol.2024.155835","volume":"154","author":"M Kokkorakis","year":"2024","unstructured":"Kokkorakis M, Boutari C, Hill MA, et al. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges. Metabolism. 2024;154:155835. https:\/\/doi.org\/10.1016\/j.metabol.2024.155835.","journal-title":"Metabolism"},{"issue":"4","key":"582_CR76","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s2468-1253(24)00049-9","volume":"9","author":"The Lancet Gastroenterology, H.","year":"2024","unstructured":"The Lancet Gastroenterology, H. Resmetirom for NASH: balancing promise and prudence. Lancet Gastroenterol Hepatol. 2024;9(4):273. https:\/\/doi.org\/10.1016\/s2468-1253(24)00049-9.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-024-00582-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-024-00582-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-024-00582-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T09:53:36Z","timestamp":1730282016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-024-00582-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":76,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["582"],"URL":"https:\/\/doi.org\/10.1007\/s13679-024-00582-z","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"25 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author's name should be \"Panagiotis Lainas\" in xml.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ming-Hua Zheng: Received honoraria for lectures from AstraZeneca, Hisky Medical Technologies and Novo Nordisk, consulting fees from Boehringer Ingelheim. Carel W le Roux: Reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards and speakers panels of Novo Nordisk, Roche, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Glia, Irish Life Health, Boehringer Ingelheim, Currax, Zealand Pharma, Keyron, AstraZeneca, and Rhythm Pharma. ClR is a member of the Irish Society for Nutrition and Metabolism outside the area of work commented on here. ClR provides obesity clinical care in the My Best Weight clinic and Beyond BMI clinic and is a shareholder in these clinics. Yusuf Yilmaz: Consultant for Zydus Therapeutics. Luca Valenti: Speaking: Viatris, Novo Nordisk, GSK; Consulting: Novo Nordisk, Pfizer, Boehringer Ingelheim, Resalis, MSD; Unrestricted grant support: Gilead. Dimitri J. Pournaras: Funded by the Royal College of Surgeons of England. He receives consulting fees from Johnson & Johnson and Novo Nordisk and payments for lectures, presentations, and educational events from Johnson & Johnson, Medtronic, and Novo Nordisk. Anna Carolina Hoff: Consultant for Boston Scientific. All other authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}